TWD
ACRV icon

True Wealth Design’s Acrivon Therapeutics ACRV Stock Holding History

True Wealth Design’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-176
Closed -$210 – 2715
2025
Q2 		$210 Buy
176
+173
+5,767% +$237 ﹤0.01% 2057
2025
Q1 		$7 Buy
+3
New +$16 ﹤0.01% 2639

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Focus Partners Wealth
Focus Partners Wealth Boston, Massachusetts $89.9B AUM 20.5% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

True Wealth Design's ACRV Position: Q3 2025 in Review

True Wealth Design sold out of Acrivon Therapeutics (ACRV) in Q3 2025, closing a stake of 176 shares — an estimated $210 sold.

True Wealth Design first reported a position in ACRV in Q1 2025 and held it in 2 quarters. The position peaked at $210 in Q2 2025. 48 funds tracked by Wall St. Rank hold ACRV as of Q3 2025.

  • True Wealth Design reported no remaining Acrivon Therapeutics position as of Q3 2025 after selling out during the quarter.
  • True Wealth Design sold 176 Acrivon Therapeutics shares in Q3 2025, an estimated $210.
  • True Wealth Design first reported a position in Acrivon Therapeutics in Q1 2025 and held it in 2 quarters.
  • True Wealth Design's Acrivon Therapeutics position peaked at $210 in Q2 2025.
  • 48 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q3 2025.

Based on True Wealth Design's 13F filing for Q3 2025, filed 21 Oct 2025.